| Fluconazole |
8–12 mg/kg/day IV |
Fungistatic activity (check for persistent candidemia).
|
| 1x/day (Max: 800 mg/day) |
Avoid using for neutropenic patients and critically ill patients. |
| Not recommended for C. krusei and C. glabrata infections. |
| Voriconazole |
2–12 years or 12–14 years and weight <40 kg: (IV): 9 mg/kg/dose on D1 2x/day and 8 mg/kg/dose 2x/day on subsequent days |
Fungistatic activity. |
| (Oral): 9 mg/kg/dose 2x/day |
Consider indication for patients with CNS infections. |
| >15 years or 12–14 years and weight >40 kg: |
Active against C. krusei.
|
| (IV): 6 mg/kg/dose on D1 2x/day and 4 mg/kg/dose 2x/day on subsequent days |
Not approved for clinical use in children < 2 years. |
| (Oral): 200 mg 2x/day |
Target serum level 1–5 mg /L. |
| Caspofungin |
70 mg/m2 (IV) on D1 |
Fungicidal activity. |
| 50 mg/m2 (IV) on subsequent days |
High MICs for C. parapsilosis are probably not clinically relevant (check for persistent candidemia).
|
| Micafungin |
2–4 mg/kg/day IV |
Fungicidal activity. |
| 1x/dia |
High MICs for C. parapsilosis are probably not clinically relevant (check for persistent candidemia).
|
| >50 kg: 100–200 mg |
| Liposomal Amphotericin B |
3 mg/kg/day IV |
Fungicidal activity. |
| 1x/day |
Usually considered for patients with deep-seated infections or Candida infections refractory to other alternatives. |
| Amphotericin B lipid complex |
5 mg/kg/day |
Fungicidal activity. |
| IV 1x/day |
Low level of evidence for its clinical use due to the lack of randomized clinical trials. |
| Usually considered for patients with deep-seated infections or Candida infections refractory to other alternatives. |
